Clinical trials: Urothelial Cancer
Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the…
- Conditions
- Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma
- Trial name
- NCT03232593
- Testing
- Atezolizumab
- Where
- 56 sites in South Korea
- Volunteers
- 1,758 people
- Sponsor
- Hoffmann-La Roche
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Urothelial Carcinoma
Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population
Urothelial carcinoma is the ninth most common malignant neoplasm worldwide. nearly in all human tumors, actin filaments are involved in lamellopodia or cellular extensions.
- Trial name
- NCT05070039
- Testing
- Expression of Cortactin anti body
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University
Urinary Bladder Urothelial Carcinoma
Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis.
- Trial name
- NCT05139134
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Carcinoma, Transitional Cell (RENI)
Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma
Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Methods: multicentered cohort study
- Trial name
- NCT06305130
- Testing
- No intervention
- Volunteers
- 2,515 people
- Sponsor
- Kaohsiung Medical University
Urothelial Carcinoma
Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan
To study the association between aristolochic acid and urothelial carcinoma in Taiwan
- Trial name
- NCT00867633
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Upper Urinary Tract Tumours
Registry for Treatment of Upper Urinary Tract Tumours
The aim of this registry is to evaluate the incidence, indications and outcomes of patients presenting with UTUC in relation to the different treatment modalities used.
- Trial name
- NCT02281188
- Where
- Netherlands
- Volunteers
- 2,451 people
- Sponsor
- Clinical Research Office of the Endourological Society
Urologic Neoplasms
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected from medical records in Stage IV urotherial (UC) patients.
- Trial name
- YODO (NCT04052113)
- Where
- Japan
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Upper Tract Urothelial Carcinoma, Bladder Recurrence
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract…
- Trial name
- NCT02547350
- Testing
- pharmorubicin or pirarubicin
- Volunteers
- 200 people
- Sponsor
- Xuesong Li
Lymph Node Dissection
Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract
Recent studies showed the therapeutic benefit of lymphadenectomy in advanced stage urothelial carcinoma of the upper urinary tract, but there is still a lack of prospective studies.
- Trial name
- NCT03474926
- Testing
- Routine Template-based lymphadenectomy, LND only for lymph nodes enlargement found in preoperative image or during surgery
- Where
- 2 sites in China
- Volunteers
- 504 people
- Sponsor
- RenJi Hospital
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Urothelial Carcinoma
B7-Family Score in Urothelial Carcinoma
Immunotherapy has been found to confer substantial survival benefits to the patients with higher mutation burdens, which become the first biomarker approved by FDA in urothelial carcinoma (UC).
- Trial name
- NCT06169904
- Testing
- Cisplatin injection
- Volunteers
- 215 people
- Sponsor
- Shanghai Zhongshan Hospital
Renal Cell Carcinoma, Urothelial Carcinoma
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT03291028
- Testing
- Immune checkpoint inhibitor targeting PD1
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer
Cost-Effectiveness in Bladder Cancer
This randomized clinical multicentre trial aims to evaluate the efficacy of microsatellite analysis on voided urine to detect tumour recurrences in the follow-up of patients with superficial urothelialcell carcinoma (UCC).
- Trial name
- NCT00126958
- Testing
- urinary analysis
- Volunteers
- 500 people
- Sponsor
- Erasmus Medical Center
Neoplasm, Ureter, Neoplasm, Bladder
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
This clinical trial is designed to compare the effect of single postoperative intravesical chemotherapy instillation versus maintenance therapy on reducing bladder cancer recurrence after surgery for UTUC.
- Trial name
- NCT02438865
- Testing
- Immediate instillation of intravesical chemotherapy-Epirubicin-, Maintainance therapy of intravesical chemotherapy-Epirubicin-
- Where
- Egypt
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Urothelial Carcinoma
Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:
Bladder cancer is common in the UK and can kill. A common sign of bladder cancer is blood in the urine (haematuria). GPs will refer to a specialist (Urologist) for further investigation of haematuria if they suspect cancer.
- Trial name
- IDENTIFY (NCT03548688)
- Where
- United Kingdom
- Volunteers
- 11,059 people
- Sponsor
- British Urology Researchers in Surgical Training
Urothelial Carcinoma
Vasculogenic Mimicry in Urothelial Carcinoma
In this study, the investigators aim at: 1. Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining. 2.
- Trial name
- NCT04295967
- Testing
- formalin fixed paraffin embedded blocks
- Volunteers
- 70 people
- Sponsor
- Assiut University
Bladder Cancer
RESECT: Improving Quality in TURBT Surgery.
Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life.
- Trial name
- RESECT (NCT05154084)
- Testing
- Performance feedback and education
- Where
- United Kingdom
- Volunteers
- 19,505 people
- Sponsor
- British Urology Researchers in Surgical Training
Bladder Cancer
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Primary Objective: 1. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone.
- Trial name
- NCT00479089
- Testing
- Docetaxel, ZD1839, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center